Palavras-chave
Como Citar
Resumo
Introduction: to estimate tumoral reduction and overall survival at one year in a series of patients with abdominal tumors treated with body fractionated stereotactic radiotherapy (SBRT). Methods: retrospective descriptive study of a series of patients with abdominal tumors (solid or hollow viscus), treated with image-guided SBRT using a CyberKnife system and who had post-treatment follow-up and control images. The study was completed at the XXXXXXX in a five-year period from January 2013 to January 2018, in XXXXXXX. Results: 16 patients were included. 75% of the cases were under 65 years of age. The treated lesions were located in the pancreas (37.5%), abdomino-pelvic lymph nodes (25%), liver (25%) and retroperitoneum (12.5%). Most of the treated patients required up to two fiduciary markers (93.7%). The SBRT dose applied ranged from 24 to 60 Gy, mostly in 3 fractions (81.3%). Mean tumoral reduction after treatment was of 15.6 mm (SD ±13.5), being statistically significant (p <0.0003). According to RECIST 1.1 criteria, a complete response was achieved in 6.2% (n=1) of the cases, a partial response in 56.3% (n=9), and stable disease in 37.5% (n=6). No disease progression was documented in any patient during the follow-up period. The one-year overall survival rate was 93.7%. Conclusion: experience at this center shows that Cyberknife radiosurgery in both primary and metastatic abdominal tumors provides, in the short term, an adequate local control rate and improved one-year overall survival.
Referências
Floriano A, Santa-Olalla I, Sanchez-Reyes A. Experience with the CyberKnife for intracranial stereotactic radiosurgery: Analysis of dosimetry indices. Medical Dosimetry 2014; 39: 1–6. doi: https://doi.org/10.1016/j.meddos.2013.08.005
Maceira Rozas M, Salvador Garrido N. Revisión de las indicaciones de la radioterapia estereotáxica corporal (SBRT) en pacientes con tumores primarios y oligometástasis. Red Española de Agencias de Evaluación de Tecnologías y Prestaciones del SNS. Axencia de Avaliación de Tecnoloxías Sanitari. 2014.
Giller CA, Berger BD. New Frontiers in Radiosurgery for the Brain and Body. Baylor University Medical Center Proceedings 2005; 18: 311–319. doi: https://doi.org/10.1080/08998280.2005.11928087
Chen J. Stereotactic Radiosurgery: Instrumentation and Theoretical Aspects--Part 1. Perm J 2005; 9: 23–26. doi: https://doi.org/10.7812/TPP/04-075
Goyal K, Einstein D, Yao M, Kunos C, Barton F, Singh D, et al. Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: Preliminary results. HPB Surgery 2010; 1–8. doi: https://doi.org/10.1155/2010/309780
Lartigau E, Mirabel X, Prevost B, Lacornerie T, Dubus F, Sarrazin T. Extracranial stereotactic radiotherapy: Preliminary results with the CyberKnife®. Oncol Res Treat 2009; 32: 209–215. doi: https://doi.org/10.1159/000200929
Kato H. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. World J Gastroenterol 2015; 21: 13101. doi: https://doi.org/10.3748/wjg.v21.i46.13101
Sotiropoulos GC, Drühe N, Sgourakis G, Molmenti EP, Beckebaum S, Baba HA, et al. Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: Which is the best oncological approach? Dig Dis Sci. 2009; 54: 2264–2273. doi: https://doi.org/10.1007/s10620-008-0604-4
Schoenberg M, Khandoga A, Stintzing S, Trumm C, Schiergens TS, Angele M, et al. CyberKnife radiosurgery – value as an adjunct to surgical treatment of HCC? Cureus 2016;8: e591. doi: https://doi.org/10.7759/cureus.591
Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008; 26: 657–664. doi: https://doi.org/10.1200/JCO.2007.14.3529
Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJM, Nowak PCJM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol (Madr). 2006; 45: 831–837. doi: https://doi.org/10.1080/02841860600897934.
Hajj C, Goodman KA. Pancreatic cancer and SBRT: A new potential option? Report Pract Oncol Radiother. 2015; 20: 377–384. doi: https://doi.org/10.1016/j.rpor.2015.05.008
Almaghrabi M, Supiot S, Paris F, Mahé M-A, Rio E. Stereotactic body radiation therapy for abdominal oligometastases: A biological and clinical review. Radiation Oncology 2012; 7: 126. doi: https://doi.org/10.1186/1748-717X-7-126
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247. https://doi.org/10.1016/j.ejca.2008.10.026.
Song Y, Yuan Z, Li F, Dong Y, Zhuang H, Wang J, et al. Analysis of clinical efficacy of CyberKnife (®) treatment for locally advanced pancreatic cancer.Onco Targets Ther 2015; 8: 1427–1431. doi: https://doi.org/10.2147/OTT.S81939
Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs Gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following presection of pancreatic adenocarcinoma. JAMA. 2008; 299: 1019. doi: https://doi.org/10.1001/jama.299.9.1019
Lischalk JW, Burke A, Chew J, Elledge C, Gurka M, Marshall J, et al. Five-fraction stereotactic body radiation therapy (SBRT) and chemotherapy for the local management of metastatic pancreatic cancer. J Gastrointest Cancer 2018; 49: 116–123. doi: https://doi.org/10.1007/s12029-016-9909-2
Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, et al. Singlefraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiation Oncol Biol Physics. 2011; 81: 181–188. doi: https://doi.org/10.1016/j.ijrobp.2010.05.006
Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiation Oncol Biol Physics. 2004; 58: 1017–1021. doi: https://doi.org/10.1016/j.ijrobp.2003.11.004
de Geus SWL, Eskander MF, Kasumova GG, Ng SC, Kent TS, Mancias JD, et al. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Cancer. 2017; 123: 4158–4167. https://doi.org/10.1002/cncr.30856.
Ihnát P, Skácelíková E, Tesař M, Penka I. Stereotactic body radiotherapy using the CyberKnife® system in the treatment of patients with liver metastases: state of the art. Onco Targets Ther. 2018; 11: 4685–4691. https://doi.org/10.2147/OTT.S165878
Dawson LA, Jaffray DA. Advances in image-guided radiation therapy. J Clin Oncol. 2007; 25: 938–946. https://doi.org/10.1200/JCO.2006.09.9515
Zhuang H-Q, Yuan Z-Y, Song Y-C, Wang J, Zhao L-J, Wang P. Clinical observation on the efficacy of CyberKnife for primary or metastatic retroperitoneal tumours. Eur J Cancer Care (Engl). 2014; 23: 76–81. https://doi.org/10.1111/ecc.12112
Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist. 2012; 17: 1100–1107. doi: https://doi.org/10.1634/theoncologist.2012-0092
Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Rad Oncol Biol Physics 2013; 86: 336–342. doi: https://doi.org/10.1016/j.ijrobp.2012.12.021
Bignardi M, Navarria P, Mancosu P, Cozzi L, Fogliata A, Tozzi A, et al. Clinical Outcome of Hypofractionated Stereotactic Radiotherapy for Abdominal Lymph Node Metastases. Int J Rad Oncol Biol Physics. 2011; 81: 831–838. doi: https:// doi.org/10.1016/j.ijrobp.2010.05.032
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2022 Lizbelky Mora-Tous, Iader Rodríguez-Márquez, Maurizio Massaro-Ceballos, John Giraldo, Esteban Jaramillo-Jiménez, David Gómez-Duque